Rekah Pharmaceutical Industry Ltd. (TLV: REKA)
Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
1,349.00
-51.00 (-3.64%)
Dec 19, 2024, 5:24 PM IDT

TLV: REKA Statistics

Total Valuation

Rekah Pharmaceutical Industry has a market cap or net worth of ILS 153.87 million. The enterprise value is 297.61 million.

Market Cap 153.87M
Enterprise Value 297.61M

Important Dates

The last earnings date was Tuesday, November 26, 2024.

Earnings Date Nov 26, 2024
Ex-Dividend Date n/a

Share Statistics

Rekah Pharmaceutical Industry has 11.41 million shares outstanding. The number of shares has increased by 9.50% in one year.

Current Share Class n/a
Shares Outstanding 11.41M
Shares Change (YoY) +9.50%
Shares Change (QoQ) +4.85%
Owned by Insiders (%) 40.54%
Owned by Institutions (%) 2.78%
Float 1.87M

Valuation Ratios

The trailing PE ratio is 19.97.

PE Ratio 19.97
Forward PE n/a
PS Ratio 0.46
PB Ratio 0.94
P/TBV Ratio 1.51
P/FCF Ratio 11.62
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 6.11, with an EV/FCF ratio of 22.47.

EV / Earnings 39.03
EV / Sales 0.90
EV / EBITDA 6.11
EV / EBIT 18.41
EV / FCF 22.47

Financial Position

The company has a current ratio of 1.43, with a Debt / Equity ratio of 0.90.

Current Ratio 1.43
Quick Ratio 0.89
Debt / Equity 0.90
Debt / EBITDA 3.03
Debt / FCF 11.13
Interest Coverage 2.24

Financial Efficiency

Return on equity (ROE) is 4.75% and return on invested capital (ROIC) is 3.09%.

Return on Equity (ROE) 4.75%
Return on Assets (ROA) 2.18%
Return on Capital (ROIC) 3.09%
Revenue Per Employee 776,571
Profits Per Employee 17,857
Employee Count 427
Asset Turnover 0.72
Inventory Turnover 2.90

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -9.32% in the last 52 weeks. The beta is 0.04, so Rekah Pharmaceutical Industry's price volatility has been lower than the market average.

Beta (5Y) 0.04
52-Week Price Change -9.32%
50-Day Moving Average 1,399.02
200-Day Moving Average 1,394.04
Relative Strength Index (RSI) 47.91
Average Volume (20 Days) 1,569

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, Rekah Pharmaceutical Industry had revenue of ILS 331.60 million and earned 7.63 million in profits. Earnings per share was 0.68.

Revenue 331.60M
Gross Profit 72.74M
Operating Income 16.11M
Pretax Income 7.62M
Net Income 7.63M
EBITDA 41.92M
EBIT 16.11M
Earnings Per Share (EPS) 0.68
Full Income Statement

Balance Sheet

The company has 3.72 million in cash and 147.41 million in debt, giving a net cash position of -143.69 million or -12.59 per share.

Cash & Cash Equivalents 3.72M
Total Debt 147.41M
Net Cash -143.69M
Net Cash Per Share -12.59
Equity (Book Value) 164.37M
Book Value Per Share 14.40
Working Capital 69.51M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 23.62 million and capital expenditures -10.37 million, giving a free cash flow of 13.25 million.

Operating Cash Flow 23.62M
Capital Expenditures -10.37M
Free Cash Flow 13.25M
FCF Per Share 1.16
Full Cash Flow Statement

Margins

Gross margin is 21.94%, with operating and profit margins of 4.86% and 2.30%.

Gross Margin 21.94%
Operating Margin 4.86%
Pretax Margin 2.30%
Profit Margin 2.30%
EBITDA Margin 12.64%
EBIT Margin 4.86%
FCF Margin 3.99%

Dividends & Yields

Rekah Pharmaceutical Industry does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -9.50%
Shareholder Yield -9.50%
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Rekah Pharmaceutical Industry has an Altman Z-Score of 1.44. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 1.44
Piotroski F-Score n/a